Please login to the form below

Not currently logged in
Email:
Password:

Celgene and GlobeImmune to collaborate

GlobeImmune has granted exclusive rights to Celgene to develop drugs intended to stimulate the immune system against cancer in a $500m deal

Research biotech GlobeImmune has granted exclusive rights to Celgene Corp to develop drugs intended to stimulate the immune system against cancer in a deal that could be worth more than $500m.

New Jersey-based Celgene will pay GlobeImmune $40m upfront, which includes an equity stake in the privately held company.

GlobeImmune, based in Louisville, will handle early-stage development of the drug candidates, called Tarmogens, and Celgene will have the option to obtain an exclusive global licence to develop and sell the drugs under the partnership.

GlobeImmune's drugs will have to meet various research milestones to trigger further payments from Celgene. The $500m potential total includes royalties Celgene would pay to GlobeImmune on future sales of drugs if they are approved.

The Tarmogen drugs contain a genetically engineered yeast that also contains antibodies designed to fight disease. The drugs are intended to boost the body's immune system. GlobeImmune has one drug, GI-4000, in mid-stage testing against pancreatic and non-small cell lung cancer. 

"The partnership with GlobeImmune supports our goal to identify and develop high-potential oncology therapies based on significant, innovative science," said Thomas Daniel, president of research for Celgene. "The Tarmogen technology has the potential to address a number of highly defined unmet medical needs."

18th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics